



DOCKET NO.: JJPR-0043

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Timothy W. Lovenberg, et al.

Application No.: 10/727,021

Filing Date: December 2, 2003

**For: DNA ENCODING A HUMAN HISTAMINE RECEPTOR OF THE H3
SUBTYPE**

Confirmation No.:

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

DATE OF DEPOSIT: *March 2, 2004*

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Felicity E. Groth

TYPED NAME: Felicity E. Groth
REGISTRATION NO.: 47,042

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☐ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).


EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☒ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
 - ☒ Copies of references **1 thru 40** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. **09/642,852**, filed **August 21, 2000**.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: March 2, 2004



Felicity E. Groth
Registration No. 47,042

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. JJPR-0043	Application No. 10/727,021
	Applicant Timothy W. Lovenberg, et al.	
	Filing Date December 2, 2003	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	1	Arrang, J.M. et al., "Autoinhibition of Brain Histamine Release Mediated by a Novel Class (H3) of Histamine Receptor", <i>Nature (London)</i> , 1983 , 302,(5911), 832-837
	2	Clark, M.A. et al., "Guanine Nucleotides and Pertussis Toxin Reduce the Affinity of Histamine H3 Receptors on AtT-20 Cells", <i>Agents Actions</i> , 1993 , 40(3-4), 129-134
	3	Clark, M.A. et al., "High Affinity Histamine H3 Receptors Regulate ACTH Release by AtT-20 Cells", <i>Eur. J. Pharmacol</i> , 1992 , 210(1), 31-35
	4	Gantz, I. et al., "Molecular Cloning of a Gene Encoding the Histamine H2 Receptor", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 1991 , 88(2), 429-433
	5	Hill, S.J. et al., "International Union of Pharmacology. XIII. Classification of Histamine Receptors", <i>Pharmacol. Rev.</i> , 1997 , 49(3), 253-278
	6	Konig, M. et al. "Method for Identifying Ligands that Bind to Cloned Gs-or Gi Coupled Receptors", <i>Mol. Cell. Neurosci</i> , 1991 , 2(4), 331-337
	7	Lovenburg, T. et al., "Cloning and Functional Expression of the Human Histamine H3 Receptor", <i>Molecular Pharmacology</i> , 1999 , 55, 1101-1107
	8	Pollard, H. et al., "A Detailed Autoradiographic Mapping of Histamine H3 Receptors in Rat Brain Areas", <i>Neuroscience</i> , 1993 , 52(1), 169-189
	9	Yamashita, M. et al., "Expression Cloning of a cDNA Encoding the Bovine Histamine H1 Receptor", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 1991 , 88(24), 11515-11519
	10	Backer, M.D. et al., "Genomic Cloning, Heterologous Expression and Pharmacological Characterization of a Human Histamine H1 Receptor", <i>Biochemical and Biophysical Research Communications</i> , December 1993 , 197(3), 1601-1608
	11	Cherifi, et al., "Purification of a Histamine H3 Receptor Negatively Coupled to Phosphoinositide Turnover in the Human Gastric Cell Line HGT1, <i>the Journal of Biological Chemistry</i> , 1992 , 267(35), 25315-25320
EXAMINER		DATE CONSIDERED

Form PTO-1449 Modified		Docket No. JJPR-0043	Application No. 10/727,021
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Timothy W. Lovenberg, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date December 2, 2003	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	12	Bellon, et al., "Purification and Biochemical Characterization of Recombinant Hirudin Produced by <i>Saccharomyces Cerevisiae</i> ", <i>Biochem</i> , 1989 , 28, 2941-2949	
	13	Ecker, et al., "Increasing Gene Expression in Yeast by Fusion to Ubiquitin", <i>J. Biol. Chem</i> , 1989 , 264(13), 7715-7719	
	14	Horowitz, et al., "Synthesis and Assembly of Functional Mammalian Na, K- ATPase in Yeast", <i>J. Biol. Chem.</i> 1990 , 265(8), 4189-4192	
	15	Jacobson, et al., "Expression and Secretion of Biologically Active Echistatin in <i>Saccharomyces Cerevisiae</i> ", <i>Gene</i> , 1989 , 85(2), 511-516	
	16	Jaso-Freidmann Liliana et al., "NCCRP-1: A Novel Receptor Protein Sequenced from Teleost Nonspecific Cytotoxic Cells", <i>Molecular Immunology</i> , 1997 , 34, 12-13), 955-965, XP002228234	
	17	Kaufman, R.J. et al., "Amplification and Expression of Sequences Contransected with a Modular Dihydrofolate Reductase Complementary DNA Gene", <i>J. Mol. Biol.</i> , 1982 , 159, 601-621	
	18	Kitts, et al., "Linearization of Baculovirus DNA Enhances the Recovery of Recombinant Virus Expression Vectors", <i>Nuc. Acid. Res.</i> , 1990 , 18(19), 5667-5672	
	19	Kohler, G. et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity", <i>Nature</i> , 1975 , 256, 495-497	
	20	Leurs, R. et al., "Therapeutic Potential of Histamine H3 Receptor Agonists and Antagonists", <i>Trends in Pharmacological Sciences, Elsevier Trends Journal</i> , 1998 , 19(5), 177-184, XP 004121095	
	21	Leurs, R. et al., "Pharmacological Characterization of the Human Histamine H2 Receptor Stably Expressed in Chinese Hamster Ovary Cells", <i>British Journal of Pharmacology</i> , 1994 , 112, 847-853, XP 002916164	
	22	Gespach, et al., <i>Journal of Clinical Investigation</i> , 1988 , 19, 1-10	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. JJPR-0043	Application No. 10/727,021
		Applicant Timothy W. Lovenberg, et al.	
		Filing Date December 2, 2003	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	23	Leurs, R. et al., "The Histamine H3-Receptor: A Target for Developing New Drugs", <i>Prog. Drug. Res.</i> , 1992 , 39, 127-165	
	24	McDonnell, et al., "Reconstitution of the Vitamin D-Responsive Osteocalcin Transcription Unit in <i>Saccharomyces Cerevisiae</i> ", <i>Mol. Cell. Biol.</i> , 1989 , 9(8), 3517-3523	
	25	Rinas, et al., "Characterization of Recombinant Factor XIIIa Produced in <i>Saccharomyces Cerevisiae</i> ", <i>Bio/Technology</i> , 1990 , 8(6), 543-546	
	26	Sabin, et al., "High-Level Expression and In Vivo Processing of Chimeric Ubiquitin Fusion Proteins in <i>Saccharomyces Cerevisiae</i> ", <i>Bio/Technology</i> , 1989 , 7(9), 705-709	
	27	Sieckevitz, et al., "Activation of the HIV-1 LTR by T Cell Mitogens and the Trans-Activator Protein of HTLV-I", <i>Science</i> , 1987 , 238, 1575-1578	
	28	Sleep, et al., "The Secretion of Human Serum Albumin from the Yeast <i>Saccharomyces Cerevisiae</i> Using Five Different Leader Sequences", <i>BioTechnology</i> , 1990 , 8, 42-46	
	29	Tedford, et al., "Development of Trans-2-[1H-imidazol-4-yl] Cyclopropane Derivatives as New High-Affinity Histamine H3 Receptor Ligands", <i>J. Pharmacol. Exper. Therapeutics</i> , 1999 , 289(2), 1160-1168	
	30	Wigler, et al., "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", <i>Cell</i> , 1977 , 11(1), 223-232	
	31	Yamamoto, et al., "Important Role of the Proline Residue in the Signal Sequence that Directs the Secretion of Human Lysozyme in <i>Saccharomyces Cerevisiae</i> ", <i>Biochemistry</i> , 1989 , 28(6), 2728-2732	
	32	Lovenburg, et al., "Cloning of Rat Histamine H3 Receptor Reveals Distinct Species Pharmacological Profiles", <i>JPET</i> , February 2000 , 293(3), 771-778	
	33	Coge, et al. "Genomic Organization and Characterization of Splice Variants of the Human Histamine H3 Receptor", <i>Biochemical Journal</i> , 2001 , 355, 279-288	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.
JJPR-0043

Application No.
10/727,021

Applicant
Timothy W. Lovenberg, et al.

Filing Date
December 2, 2003

Group
Not Yet Assigned

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	34	5,817,480	10/06/98	Murry, et al.	435	69
	35	5,882,893	03/16/99	Goodearl	435	69
	36	6,136,559	10/24/00	Lovenberg, et al.	435	69.1
	37	6,413,743 B1	07/02/02	Lovenberg, et al.	435	69.1
	38	6,437,100 B1	08/20/02	Lovenberg, et al.	530	391.1

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	39	EP 1 043 395 A1	10/11/00	EPO		
	40	WO 99/28470	06/10/99	PCT		

EXAMINER**DATE CONSIDERED**